<DOC>
	<DOCNO>NCT03060980</DOCNO>
	<brief_summary>A Phase 3b , open-label , randomize , multicenter , efficacy , safety , tolerability study ITCA 650 compare Empagliflozin Glimepiride , add-on therapy Metformin patient Type 2 diabetes .</brief_summary>
	<brief_title>Comparison Efficacy , Safety , Tolerability ITCA 650 Empagliflozin Glimepiride add-on Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosis T2D 3 month prior Screening Visit . Body mass index ( BMI ) ≥25 ≤45 kg/m2 Screening Visit . Glycosylated hemoglobin A1c ( HbA1c ) ≥7.5 ≤10.5 % . 5 . 6 . On stable ( 3 month prior Screening Visit ) treatment regimen metformin monotherapy ≥1500 mg/day ) . History type 1 diabetes . Prior participation clinical study involve ITCA 650 . Treatment GLP1 receptor agonist ( eg , liraglutide , exenatide ) within 6 month prior Screening . History evidence , within last 6 month prior Screening Visit , myocardial infarction , coronary revascularization ( coronary artery bypass graft percutaneous coronary intervention ) , unstable angina , cerebrovascular accident stroke . History evidence acute chronic pancreatitis . History medullary thyroid cancer family personal history multiple endocrine neoplasia type 2 . Treatment medication affect GI motility . History hypersensitivity exenatide , empagliflozin , glimepiride one excipients . Women pregnant , lactating , plan become pregnant . Chronic ( &gt; 10 consecutive day ) treatment systemic corticosteroid within 8 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>